Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide

Y. Sun, S. H. Kim, D. C. Zhou, W. Ding, Elisabeth M. Paietta, F. Guidez, A. Zelent, K.h. Ramesh, L. Cannizzaro, R. P. Warrell, R. E. Gallagher

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

AP-1060 is a newly established acute promyelocytic leukemia (APL) cell line from a multiple-relapse patient clinically resistant to both all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). The line was initially derived as a granulocyte colony-stimulating factor-dependent strain that underwent replicative senescence and, following ethylnitrosourea treatment, as a phenotypically similar immortalized line. Immortalization was associated with broadened cytokine sensitivity but not growth autonomy, in contrast to three previously derived APL lines. Both the AP-1060 strain and line had shortened telomeres and low telomerase activity, while the line had higher expression of many genes associated with macromolecular synthesis. The karyotype was 46,XY,t(3;14)(p21.1;q11.2),t(15;17)(q22;q11) [100%]; the unique t(3;14) was observed in 4/9 t(15;17)-positive metaphase cells at previous relapse on ATRA therapy. The PML-RARα mRNA harbored a missense mutation in the RARα-region ligand-binding domain (Pro900Ser). This was associated with a right-shift and sharpening of the ATRA-induced maturation response compared to ATRA-sensitive NB4 cells, which corresponded to the transcriptional activation by PML-RARαω Prog900Ser of a cotransfected ATRA-targeted reporter vector in COS-1 cells. AP-1060 also manifested relative resistance to ATO-induced apoptosis at ≥ 1 μM, while 0.25 μM ATO stimulated limited atypical maturation. These findings suggest that AP-1060 will be useful for further assessing molecular elements involved in APL progression and drug response/resistance.

Original languageEnglish (US)
Pages (from-to)1258-1269
Number of pages12
JournalLeukemia
Volume18
Issue number7
DOIs
StatePublished - Jul 2004

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Cytokines
Cell Line
Ethylnitrosourea
Telomere Shortening
Recurrence
Cell Aging
Telomerase
COS Cells
Granulocyte Colony-Stimulating Factor
Missense Mutation
Metaphase
Karyotype
Drug Resistance
Transcriptional Activation
arsenic trioxide
Apoptosis
Ligands
Gene Expression

Keywords

  • Acute promyelocytic leukemia
  • Arsenic trioxide resistance
  • Cell strain immortalization
  • Cytokine-dependent cell line
  • Retinoic acid resistance

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide. / Sun, Y.; Kim, S. H.; Zhou, D. C.; Ding, W.; Paietta, Elisabeth M.; Guidez, F.; Zelent, A.; Ramesh, K.h.; Cannizzaro, L.; Warrell, R. P.; Gallagher, R. E.

In: Leukemia, Vol. 18, No. 7, 07.2004, p. 1258-1269.

Research output: Contribution to journalArticle

Sun, Y. ; Kim, S. H. ; Zhou, D. C. ; Ding, W. ; Paietta, Elisabeth M. ; Guidez, F. ; Zelent, A. ; Ramesh, K.h. ; Cannizzaro, L. ; Warrell, R. P. ; Gallagher, R. E. / Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide. In: Leukemia. 2004 ; Vol. 18, No. 7. pp. 1258-1269.
@article{c20db283ba9d450b826322beeb15f2b5,
title = "Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide",
abstract = "AP-1060 is a newly established acute promyelocytic leukemia (APL) cell line from a multiple-relapse patient clinically resistant to both all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). The line was initially derived as a granulocyte colony-stimulating factor-dependent strain that underwent replicative senescence and, following ethylnitrosourea treatment, as a phenotypically similar immortalized line. Immortalization was associated with broadened cytokine sensitivity but not growth autonomy, in contrast to three previously derived APL lines. Both the AP-1060 strain and line had shortened telomeres and low telomerase activity, while the line had higher expression of many genes associated with macromolecular synthesis. The karyotype was 46,XY,t(3;14)(p21.1;q11.2),t(15;17)(q22;q11) [100{\%}]; the unique t(3;14) was observed in 4/9 t(15;17)-positive metaphase cells at previous relapse on ATRA therapy. The PML-RARα mRNA harbored a missense mutation in the RARα-region ligand-binding domain (Pro900Ser). This was associated with a right-shift and sharpening of the ATRA-induced maturation response compared to ATRA-sensitive NB4 cells, which corresponded to the transcriptional activation by PML-RARαω Prog900Ser of a cotransfected ATRA-targeted reporter vector in COS-1 cells. AP-1060 also manifested relative resistance to ATO-induced apoptosis at ≥ 1 μM, while 0.25 μM ATO stimulated limited atypical maturation. These findings suggest that AP-1060 will be useful for further assessing molecular elements involved in APL progression and drug response/resistance.",
keywords = "Acute promyelocytic leukemia, Arsenic trioxide resistance, Cell strain immortalization, Cytokine-dependent cell line, Retinoic acid resistance",
author = "Y. Sun and Kim, {S. H.} and Zhou, {D. C.} and W. Ding and Paietta, {Elisabeth M.} and F. Guidez and A. Zelent and K.h. Ramesh and L. Cannizzaro and Warrell, {R. P.} and Gallagher, {R. E.}",
year = "2004",
month = "7",
doi = "10.1038/sj.leu.2403372",
language = "English (US)",
volume = "18",
pages = "1258--1269",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide

AU - Sun, Y.

AU - Kim, S. H.

AU - Zhou, D. C.

AU - Ding, W.

AU - Paietta, Elisabeth M.

AU - Guidez, F.

AU - Zelent, A.

AU - Ramesh, K.h.

AU - Cannizzaro, L.

AU - Warrell, R. P.

AU - Gallagher, R. E.

PY - 2004/7

Y1 - 2004/7

N2 - AP-1060 is a newly established acute promyelocytic leukemia (APL) cell line from a multiple-relapse patient clinically resistant to both all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). The line was initially derived as a granulocyte colony-stimulating factor-dependent strain that underwent replicative senescence and, following ethylnitrosourea treatment, as a phenotypically similar immortalized line. Immortalization was associated with broadened cytokine sensitivity but not growth autonomy, in contrast to three previously derived APL lines. Both the AP-1060 strain and line had shortened telomeres and low telomerase activity, while the line had higher expression of many genes associated with macromolecular synthesis. The karyotype was 46,XY,t(3;14)(p21.1;q11.2),t(15;17)(q22;q11) [100%]; the unique t(3;14) was observed in 4/9 t(15;17)-positive metaphase cells at previous relapse on ATRA therapy. The PML-RARα mRNA harbored a missense mutation in the RARα-region ligand-binding domain (Pro900Ser). This was associated with a right-shift and sharpening of the ATRA-induced maturation response compared to ATRA-sensitive NB4 cells, which corresponded to the transcriptional activation by PML-RARαω Prog900Ser of a cotransfected ATRA-targeted reporter vector in COS-1 cells. AP-1060 also manifested relative resistance to ATO-induced apoptosis at ≥ 1 μM, while 0.25 μM ATO stimulated limited atypical maturation. These findings suggest that AP-1060 will be useful for further assessing molecular elements involved in APL progression and drug response/resistance.

AB - AP-1060 is a newly established acute promyelocytic leukemia (APL) cell line from a multiple-relapse patient clinically resistant to both all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). The line was initially derived as a granulocyte colony-stimulating factor-dependent strain that underwent replicative senescence and, following ethylnitrosourea treatment, as a phenotypically similar immortalized line. Immortalization was associated with broadened cytokine sensitivity but not growth autonomy, in contrast to three previously derived APL lines. Both the AP-1060 strain and line had shortened telomeres and low telomerase activity, while the line had higher expression of many genes associated with macromolecular synthesis. The karyotype was 46,XY,t(3;14)(p21.1;q11.2),t(15;17)(q22;q11) [100%]; the unique t(3;14) was observed in 4/9 t(15;17)-positive metaphase cells at previous relapse on ATRA therapy. The PML-RARα mRNA harbored a missense mutation in the RARα-region ligand-binding domain (Pro900Ser). This was associated with a right-shift and sharpening of the ATRA-induced maturation response compared to ATRA-sensitive NB4 cells, which corresponded to the transcriptional activation by PML-RARαω Prog900Ser of a cotransfected ATRA-targeted reporter vector in COS-1 cells. AP-1060 also manifested relative resistance to ATO-induced apoptosis at ≥ 1 μM, while 0.25 μM ATO stimulated limited atypical maturation. These findings suggest that AP-1060 will be useful for further assessing molecular elements involved in APL progression and drug response/resistance.

KW - Acute promyelocytic leukemia

KW - Arsenic trioxide resistance

KW - Cell strain immortalization

KW - Cytokine-dependent cell line

KW - Retinoic acid resistance

UR - http://www.scopus.com/inward/record.url?scp=3142667730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142667730&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403372

DO - 10.1038/sj.leu.2403372

M3 - Article

VL - 18

SP - 1258

EP - 1269

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -